Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. See why I think AQST stock is a buy ...

And since a lot of innovations usually come from smaller players, there is not one big leader that Viatris has to displace to gain shares. New launches include Tyrvaya, first and only nasal spray ...

ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future ...

The nasal spray, dubbed neffy, has been filed for use in adults and children weighing 30 mg or more as an alternative to epinephrine injections such as Kaléo’s AUVI-Q and Viatris’ EpiPen ...

Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics.

Paratek Pharmaceuticals to acquire Optinose and its nasal drug-device Xhance for up to $330M, expanding beyond antibiotics ...

Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. Viatris beat analysts’ revenue expectations by 1% last quarter ...

CINCINNATI (WKRC) - The Food and Drug Administration issued a recall for certain nasal spray that tested positive for a bacterial contaminate that could lead to "potentially life-threatening ...

In this article, we are going to take a look at where Viatris Inc. (NASDAQ:VTRS) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past two ...

CANONSBURG, Pa. (AP) — CANONSBURG, Pa. (AP) — Viatris Inc (VTRS) on Thursday reported a loss of $516.5 million in its fourth quarter. The Canonsburg, Pennsylvania-based company said it had a ...

PITTSBURGH, Feb. 27, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on February 24, 2025, its Board of Directors approved a 2025 dividend policy of 48 cents ($0.48 ...